Cardiovascular Disease Archives - Hematology Advisor

The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.

Initiation of Biologic DMARDs Associated with Increased VTE Risk

Thrombotic Disorders

Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE

By

Brian Park, PharmD

September 23, 2019

Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…

Thrombotic Disorders

Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study

By

Steve Duffy

July 8, 2019

Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.

Bleeding Disorders

Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Tx Designation

By

Diana Ernst, RPh

April 10, 2019

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.